A patient is undergoing a physical and reveals a history of chicken pox. The doctor states he doesn't need a vaccine for chicken pox anymore since he has already been exposed to the disease. What type of immunity does this describe?

A. "Continuing captopril during pregnancy will not pose any risks to the developing fetus.":Captopril is an ACE inhibitor and is contraindicated in pregnancy due to its high risk of causing fetal malformations, renal failure, or death. Continuing the drug during pregnancy is unsafe and can lead to serious fetal harm.

B. "Switching to another ACE inhibitor is advisable to reduce the risk of teratogenic effects during pregnancy.": All ACE inhibitors carry similar teratogenic risks. Switching to another ACE inhibitor does not eliminate fetal risk. An alternative antihypertensive from a safer class is required.

C. "It is safe to take captopril during the first trimester as the teratogenic effects only occur later in pregnancy.":Teratogenic effects of ACE inhibitors can occur in any trimester, especially affecting fetal renal development in the second and third trimesters. First-trimester exposure can also cause congenital malformations. Use during any stage is unsafe.

D. "Captopril should be discontinued and replaced with an alternative to avoid teratogenic effects on the fetus":Discontinuing captopril before pregnancy and using a safer antihypertensive (e.g., labetalol or methyldopa) reduces the risk of fetal malformations and adverse pregnancy outcomes. Patient education on medication adjustment prior to conception is essential for safety.

A. The statins increase HDL and decrease LDL by inhibiting an enzyme that synthesizes cholesterol in the liver:Statins inhibit HMG-CoA reductase, the enzyme responsible for cholesterol synthesis in the liver. This reduces LDL production and modestly increases HDL, improving the lipid profile and reducing cardiovascular risk.

B. Increasing the synthesis of cholesterol in hepatocytes:Statins do not increase cholesterol synthesis; they inhibit it. Increasing cholesterol production would worsen hyperlipidemia, which is contrary to the therapeutic goal.

C. Increasing the production of VLDL, the primary carrier of triglycerides:Statins primarily reduce LDL cholesterol, not VLDL production. Increasing VLDL would elevate triglycerides and exacerbate lipid disorders.

D. Decreasing the number of LDL receptors in the bloodstream:Statins actually increase LDL receptor expression on hepatocytes, enhancing clearance of LDL from the blood. Decreasing LDL receptors would raise LDL levels, which is the opposite of the intended effect.